Literature DB >> 26635141

rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R.

Augustin Luna1, Vinodh N Rajapakse2, Fabricio G Sousa3, Jianjiong Gao4, Nikolaus Schultz4, Sudhir Varma2, William Reinhold2, Chris Sander1, Yves Pommier2.   

Abstract

PURPOSE: The rcellminer R package provides a wide range of functionality to help R users access and explore molecular profiling and drug response data for the NCI-60. The package enables flexible programmatic access to CellMiner's unparalleled breadth of NCI-60 data, including gene and protein expression, copy number, whole exome mutations, as well as activity data for ∼21K compounds, with information on their structure, mechanism of action and repeat screens. Functions are available to easily visualize compound structures, activity patterns and molecular feature profiles. Additionally, embedded R Shiny applications allow interactive data exploration.
AVAILABILITY AND IMPLEMENTATION: rcellminer is compatible with R 3.2 and above on Windows, Mac OS X and Linux. The package, documentation, tutorials and Shiny-based applications are available through Bioconductor (http://www.bioconductor.org/packages/rcellminer); ongoing updates will occur according to the Bioconductor release schedule with new CellMiner data. The package is free and open-source (LGPL 3). CONTACT: lunaa@cbio.mskcc.org or vinodh.rajapakse@nih.gov. Published by Oxford University Press 2015. This work is written by US Government employees and is in the public domain in the US.

Mesh:

Year:  2015        PMID: 26635141      PMCID: PMC4907377          DOI: 10.1093/bioinformatics/btv701

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  7 in total

1.  fmcsR: mismatch tolerant maximum common substructure searching in R.

Authors:  Yan Wang; Tyler W H Backman; Kevin Horan; Thomas Girke
Journal:  Bioinformatics       Date:  2013-08-20       Impact factor: 6.937

2.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

3.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

Authors:  William C Reinhold; Margot Sunshine; Hongfang Liu; Sudhir Varma; Kurt W Kohn; Joel Morris; James Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2012-07-15       Impact factor: 12.701

4.  The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Authors:  Ogan D Abaan; Eric C Polley; Sean R Davis; Yuelin J Zhu; Sven Bilke; Robert L Walker; Marbin Pineda; Yevgeniy Gindin; Yuan Jiang; William C Reinhold; Susan L Holbeck; Richard M Simon; James H Doroshow; Yves Pommier; Paul S Meltzer
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

Review 5.  Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.

Authors:  William C Reinhold; Sudhir Varma; Vinodh N Rajapakse; Augustin Luna; Fabricio Garmus Sousa; Kurt W Kohn; Yves G Pommier
Journal:  Hum Genet       Date:  2014-09-12       Impact factor: 4.132

6.  RTCGAToolbox: a new tool for exporting TCGA Firehose data.

Authors:  Mehmet Kemal Samur
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

7.  ChemmineR: a compound mining framework for R.

Authors:  Yiqun Cao; Anna Charisi; Li-Chang Cheng; Tao Jiang; Thomas Girke
Journal:  Bioinformatics       Date:  2008-07-02       Impact factor: 6.937

  7 in total
  18 in total

1.  TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Authors:  Muthana Al Abo; Hiroyuki Sasanuma; Xiaojun Liu; Vinodh N Rajapakse; Shar-Yin Huang; Evgeny Kiselev; Shunichi Takeda; William Plunkett; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.261

2.  The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.

Authors:  Laetitia Marzi; Yilun Sun; Shar-Yin N Huang; Amy James; Simone Difilippantonio; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2020-05-19       Impact factor: 6.261

3.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

4.  Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.

Authors:  Eriko Katsuta; Li Yan; Masayuki Nagahashi; Ali Raza; Jamie L Sturgill; Debra E Lyon; Omar M Rashid; Nitai C Hait; Kazuaki Takabe
Journal:  J Surg Res       Date:  2017-06-29       Impact factor: 2.192

Review 5.  Pharmacogenomics and big genomic data: from lab to clinic and back again.

Authors:  Adam Lavertu; Greg McInnes; Roxana Daneshjou; Michelle Whirl-Carrillo; Teri E Klein; Russ B Altman
Journal:  Hum Mol Genet       Date:  2018-05-01       Impact factor: 6.150

6.  Correlating Chemical Sensitivity with Low Level Activation of Mechanotransduction Pathways in Hematologic Malignancies.

Authors:  Robert G Hawley
Journal:  Explor Res Hypothesis Med       Date:  2017-09-11

7.  Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Authors:  Laetitia Marzi; Keli Agama; Junko Murai; Simone Difilippantonio; Amy James; Cody J Peer; William D Figg; Daniel Beck; Mohamed S A Elsayed; Mark Cushman; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2018-05-10       Impact factor: 6.261

Review 8.  Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy.

Authors:  José E Belizário; Beatriz A Sangiuliano; Marcela Perez-Sosa; Jennifer M Neyra; Dayson F Moreira
Journal:  Front Pharmacol       Date:  2016-09-29       Impact factor: 5.810

Review 9.  Computational models for predicting drug responses in cancer research.

Authors:  Francisco Azuaje
Journal:  Brief Bioinform       Date:  2017-09-01       Impact factor: 11.622

10.  ONC201 kills breast cancer cells in vitro by targeting mitochondria.

Authors:  Yoshimi Endo Greer; Natalie Porat-Shliom; Kunio Nagashima; Christina Stuelten; Dan Crooks; Vishal N Koparde; Samuel F Gilbert; Celia Islam; Ashley Ubaldini; Yun Ji; Luca Gattinoni; Ferri Soheilian; Xiantao Wang; Markus Hafner; Jyoti Shetty; Bao Tran; Parthav Jailwala; Maggie Cam; Martin Lang; Donna Voeller; William C Reinhold; Vinodh Rajapakse; Yves Pommier; Roberto Weigert; W Marston Linehan; Stanley Lipkowitz
Journal:  Oncotarget       Date:  2018-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.